FDA Inspection 1142696 — Jiangsu Sihuan Bioengineering Pharmaceutical Co., Ltd.
The FDA completed an inspection of Jiangsu Sihuan Bioengineering Pharmaceutical Co., Ltd. on May 21, 2021 in Wuxi. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- May 21, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuxi (China)